Drug Database
IN

interferon

✓ Approved

HK inno.N · IFNAR2 · 重组蛋白

什么是 interferon?

interferon 是一种重组蛋白,由HK inno.N研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Topical。

药物档案

公司HK inno.N
药物类别重组蛋白
分子靶点IFNAR2
给药途径Injectable (Others), Topical
状态Approved

作用机制

分子靶点

interferon 作用于 1 个分子靶点:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

interferon 针对 6 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hairy cell leukaemia✓ Approved
Infections and infestationsHepatitis B✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Renal cancer✓ Approved

注册免费账户还可查看另外 1 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedNature communications2026-11-19

Tumor-intrinsic PTPN12 suppresses anti-tumor immunity in colorectal cancer by restraining a dual epigenetic and cytoskeletal dsRNA sensing program.

Huo Yachang Y, Tian Yijun Y, Wang Dan D, Ping Yu Y et al.

Innate sensing of endogenous double-stranded RNA and the ensuing interferon response are crucial for the efficacy of immune checkpoint inhibition. Microsatellite stable colorectal cancer characteristically lacks this response, remaining immune-refractory with undefined intrinsic regulators. Here, through an in vivo clustered regularly interspaced short palindromic repeats screen, we identify PTPN12 as a physiological barrier that suppresses double-stranded RNA sensing and interferon response. TRIM28 was identified as a direct PTPN12 substrate here; PTPN12 removes phosphorylation at Y370 to stabilize repressive complexes and silence transposable elements, while concurrently rewiring the adhesive cytoskeleton to disrupt the spatially organization of cytosolic double-stranded RNA required for efficient innate sensing. Pharmacological inducible PTPN12 knockdown inhibits pre-established tumor growth and overcomes immunotherapy resistance in vivo, recapitulating PTPN12 ablation-induced massive double-stranded RNA accumulation. Our findings reveal a role for PTPN12 in coupling epigenetic silencing with cytoskeletal surveillance, suggesting potential strategies to augment anti-tumor immunity and overcome immunotherapy resistance in microsatellite stable colorectal cancer.

PMID 43052240
阅读全文 →
PubMedPulmonology2026-11-19

Nebulized interferon-β1a (SNG001) in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.

Qin Jinlv J, Wang Guizuo G, Han Dong D

This systematic review and meta-analysis aimed to determine the efficacy of nebulised interferon-β1a (SNG001) in patients with Coronavirus disease-2019 (COVID-19). A systematic search was conducted across PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Studies were searched up to November 2025. Randomised controlled trials (RCTs) on treatment of COVID-19 with SNG001, compared with placebo or standard of care, were reviewed. Data were analysed using the RevMan Version 5.1 (The Cochrane Collaboration). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. Four RCTs (enrolling 1055 participants) met the inclusion criteria. The proportion of patients with hospitalisations (data extracted from two RCTs) (RR 0.16, 95% CI 0.03 to 0.88), and serious adverse events (RR 0.65, 95% CI 0.47 to 0.90) were significantly fewer in SNG001 groups. There was no statistically significant difference in all-cause mortality (RR 0.72, 95% CI 0.37 to 1.39), patients non-recovery at day 28 (RR 0.87, 95% CI 0.65 to 1.17), and adverse event (RR 0.97, 95% CI 0.90 to 1.04) between the two groups. Nebulised SNG001 was safe and associated with a reduction in COVID-19-related hospital admission. SNG001 shows a potential benefit for outpatients with COVID-19, but it requires larger clinical trials for future validations, particularly in vaccinated and previously infected populations.

PMID 43053745
阅读全文 →
PubMedCancer immunology, immunotherapy : CII2026-11-19

Tumor-associated antigen-reactive T cells and clinical outcomes in head and neck squamous cell carcinoma treated with pembrolizumab plus chemotherapy.

Sato Ryosuke R, Sakaue Shota S, Ominato Hisataka H, Inoue Takahiro T et al.

Blood-based biomarkers associated with clinical outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab plus chemotherapy remain poorly defined. We investigated 38 patients with HNSCC treated with pembrolizumab plus 5-fluorouracil and platinum (FP). Baseline systemic inflammation and immune status were assessed using routine laboratory parameters. Peripheral blood mononuclear cells were analyzed by flow cytometry to assess exhaustion- and activation-associated markers on CD4⁺ and CD8⁺ T cells, including CD38, Tim-3, PD-1, and ICOS. Tumor-associated antigen (TAA)-reactive immune responses were evaluated by interferon-γ production following stimulation with epidermal growth factor receptor (EGFR)- and c-Met-derived peptides. PD-L1 CPS positivity, elevated neutrophil-to-lymphocyte ratio, and higher frequencies of CD8⁺CD38⁺ T cells were associated with clinical outcomes, with similar trends observed for selected inflammatory and peripheral T-cell activation/exhaustion-associated markers. Tumor-associated antigen-reactive immune responses were detected in a subset of patients and were associated with prolonged progression-free survival, while EGFR peptide reactivity was additionally associated with improved overall survival. In this exploratory study, immune reactivity to TAAs was associated with favorable clinical outcomes in patients receiving pembrolizumab plus FP. Together with systemic inflammation and peripheral T-cell activation/exhaustion markers, these findings support further evaluation of integrated blood-based immune profiling, including TAA-reactive immune responses, as candidate biomarkers in larger prospective cohorts.

PMID 43052553
阅读全文 →
PubMedBMC medical genomics2026-11-19

Effect of SP110 single nucleotide polymorphisms on expression of selected cytokines in a Ugandan population with pulmonary tuberculosis.

Kyabaggu Denis S DS, Namuganga Anna Ritah AR, Muruhukye Jacob J, Katagirya Eric E et al.

The SP110 (speckled protein 110) is a nuclear body protein resulting from the expression of an interferon-stimulated gene crucial for macrophage-mediated killing of Mycobacterium tuberculosis (Mtb), the etiologic agent for human pulmonary tuberculosis (PTB). SP110 single nucleotide polymorphisms (SNPs) have been associated with susceptibility to PTB in different populations. However, the influence of SP110 genetic variants on quantitative host cytokine responses during active PTB remains poorly characterized, particularly in East African populations. We systematically evaluated the association between ten SP110 SNPs and plasma concentrations of six key immunoregulatory cytokines, IL-4, IL-6, IL-10, IFN-γ, TNF, and IFN-α, among bacteriologically confirmed PTB patients in Kampala, Uganda. We conducted a cross-sectional molecular epidemiological study among 153 adults with bacteriologically confirmed PTB recruited from Mulago National Referral Hospital and Kisenyi Health Centre IV, Kampala, Uganda. SP110 SNP genotyping was performed using a validated mass array protocol. Plasma cytokine concentrations were quantified by Luminex multiplex bead-based immunoassay and log₂-transformed before analysis. Genotype-phenotype associations were evaluated under additive, dominant, and recessive genetic inheritance models using multivariable generalized linear models adjusted for age, sex, HIV status, TB treatment status, and BCG vaccination scar. Multiple testing was controlled using the Benjamini-Hochberg false discovery rate (FDR) procedure. Multivariate immune profiling was conducted using Spearman correlation matrices and principal component analysis (PCA). Eight of the ten SP110 SNPs satisfied Hardy Weinberg Equilibrium (HWE), while rs11556887 and rs1427294 were near-monomorphic among the participants. All six cytokines were strongly intercorrelated (Spearman ρ = 0.38-0.85, all p < 0.001), and PCA demonstrated that a single dominant principal component, driven by IL-4, IFN-γ, TNF, IFN-α, and IL-10, explained 76.6% of inter-individual cytokine variance, reflecting a coordinated innate-adaptive immune response. One association survived Benjamini-Hochberg FDR correction: rs7580900 was significantly associated with IL-10 (β = - 2.02, 95% CI: - 3.03 to - 1.02, p < 0.001, FDR q = 0.019). Additional nominally significant associations (p < 0.05) were observed for rs2241525 and rs3948464 with IL-6 and IL-10 and for rs7580900 and rs3948464 with IFN-γ, though none of these secondary associations survived FDR correction. We report a significant association of SP110 rs7580900 with reduced IL-10 plasma concentrations among Ugandan PTB patients, implicating this variant in the modulation of anti-inflammatory regulatory responses during active Mtb infection. The strong cytokine co-expression profile observed across suggests a coordinated nature of the PTB immune response. The identified immune network structure supports the development of host-directed therapeutic strategies targeting cytokine regulation. Genetic screening of key regulatory variants such as SP110 rs7580900 may also contribute to innovative precision medicine approaches for tuberculosis management.

PMID 43053010
阅读全文 →
PubMedFrontiers in pharmacology2026-11-18

Pretreatment with Commelina communis L. improves survival following influenza a virus infection and enhances innate interferon signaling.

Kwon Eun-Bin EB, Yang Hye Jin HJ, Kim Buyun B, Li Wei W et al.

The objectives of this study were to evaluate the pre-exposure protective effects of Commelina communis L. (CCL) against influenza A virus (IAV) infection and to investigate its associated immunomodulatory mechanisms. Using RAW 264.7 cells and BALB/c mouse models, we demonstrated that CCL pretreatment reduced viral replication markers and suppressed viral protein expression in vitro. In vivo, prophylactic administration of CCL improved survival from 0% to 40% and attenuated body-weight loss following IAV challenge. Mechanistically, CCL enhanced the secretion of type I interferon IFN-β through activation of TANK-binding kinase 1 (TBK1) and interferon regulatory factors 3 and 7 (IRF3/7). Activation of this signaling pathway was associated with STAT1/2 phosphorylation and increased expression of antiviral interferon-stimulated genes, including Isg20 and Isg56. Phytochemical profiling using ultra-high-performance liquid chromatography coupled with quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-UV-HRMS) identified four phytochemicals in CCL, among which rutin showed the greatest activity among the tested compounds in the in vitro screening assay. Collectively, these findings suggest that CCL and rutin may enhance host antiviral defense by modulating innate interferon signaling when administered before IAV exposure period.

PMID 43048016
阅读全文 →
PubMedFrontiers in immunology2026-11-18

Interferon-induced transmembrane protein 3 (IFITM3) as a neuroimmune regulator in Alzheimer's disease: emerging roles in astrocyte activation and pathological signaling.

Zhang Tianying T, Huang Jiangtao J, Wang Haoping H, Li Jing J et al.

Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, Tau pathology, and persistent neuroinflammation. Although therapeutic strategies targeting Aβ and Tau have significantly advanced our understanding of AD pathogenesis, growing attention has been directed toward the role of immune dysregulation in AD progression, highlighting the need to identify immune regulators that contribute to AD-associated pathological mechanisms. Interferon-induced transmembrane protein 3 (IFITM3), an interferon-responsive membrane protein involved in innate immune responses, has recently emerged as a potential regulator of AD-associated pathological processes. Experimental and transcriptomic studies suggest that IFITM3 modulates γ-secretase activity, amyloidogenic processing, inflammatory activation, and membrane trafficking pathways. Notably, IFITM3 is enriched in reactive astrocyte populations, raising the possibility that astrocytic IFITM3 contributes to the regulation of interferon-associated glial responses and neuroinflammatory signaling. In this review, we summarize current evidence regarding the role of IFITM3 in AD, focusing on astrocyte-associated mechanisms, including inflammatory regulation, endo-lysosomal dysfunction, and extracellular vesicle-mediated communication. We further discuss IFITM3-related signaling across astrocytes, neurons, microglia, vascular cells, and peripheral immune compartments, as well as emerging therapeutic approaches targeting IFITM3-associated pathways. Collectively, current evidence suggests that IFITM3 may serve as a potential regulatory interface connecting interferon activation, neuroimmune dysregulation, amyloid metabolism, and neuroinflammatory signaling, providing new perspectives on astrocyte-mediated mechanisms and therapeutic intervention in AD.

PMID 43048173
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多interferon